Heart shield for breast cancer patients: Beta-Blocker may prevent Chemo-Induced damage

NCT ID NCT03879629

Terminated Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the beta-blocker carvedilol can prevent or treat heart problems in breast cancer patients receiving HER2-targeted therapy. About 184 adults with HER2-positive breast cancer will be randomly assigned to take carvedilol either preventatively or only after signs of heart injury appear. The goal is to find the best timing and duration for heart protection during cancer treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic

Phoenix, Arizona, 85054, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Washington University in St. Louis

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.